Abstract
The prognosis of patients with chronic myeloid leukemia has dramatically improved along with the progress of therapy. However, some concerns remain unresolved, and new treatment strategies have been implemented recently. In this Progress in Hematology corner, the following four issues are presented and discussed: (1) Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: Differences and similarities; (2) Asciminib as a third-line option in chronic myeloid leukemia; (3) Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia; and (4) Genetic landscape of chronic myeloid leukemia. All these review articles will provide critical information for hematologists and let us know things we should learn in order to treat patients with this disease adequately.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
